This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of SAMe for Hot Flashes (SAMe)

This study has been completed.
Information provided by (Responsible Party):
Mayo Clinic Identifier:
First received: June 8, 2010
Last updated: April 10, 2014
Last verified: April 2014

RATIONALE: S-adenosyl-L-methionine may help relieve hot flashes in women based upon its ability to potentially modulate serotonin.

PURPOSE: This phase II trial is studying the side effects and how well s-adenosyl-L-methionine works in treating hot flashes in women with a history of breast cancer or those who do not wish to take estrogen due to a perceived increased risk of breast cancer.

Condition Intervention Phase
Healthy, no Evidence of Disease Hot Flashes Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate Other: questionnaire administration Procedure: quality-of-life assessment Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Evaluation of S-Adenosyl-L-Methionine (SAMe) for the Treatment of Hot Flashes

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Percent of Baseline in Average Hot Flash Activity (Score and Frequency) [ Time Frame: From baseline to week 7 ]
    Hot flash score was defined as the number of mild hot flashes for the week plus two times the number of moderate hot flashes plus three times the number of severe hot flashes plus four times the number of very severe hot flashes. Hot flash frequency was defined as the average number of hot flashes per day for each week. Week 7 percent of baseline was calculated. The reduction in hot flash score and frequency can be calculated by subtracting the week 7 percent of baseline from 100 percent.

Secondary Outcome Measures:
  • Change From Baseline in Self-assessment Items [ Time Frame: End of study ]
  • Adverse Event Grade Incidence [ Time Frame: End of study ]

Enrollment: 45
Study Start Date: October 2010
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Given orally
Other Name: SAMe disulfate p-toluene-sulfonate
Other: questionnaire administration
Ancillary studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment

Detailed Description:


I. To evaluate the impact of SAMe on hot flash scores in women with a history of breast cancer or women who do not wish to take estrogen therapy for fear of increased risk of breast cancer.

II. To evaluate the toxicity of SAMe in this study population. III. To evaluate the effect of SAMe using quality-of-life (QOL) measures.


During the first week, participants will complete a daily, prospective hot flash diary and complete baseline questionnaires and will not be taking any study medication. After this baseline week, participants will receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women with a history of breast cancer (currently without malignant disease) or women who have no history of breast cancer but who wish to avoid estrogen due to a perceived increased risk of breast cancer
  • Bothersome hot flashes (defined by their occurrence >= 14 times per week and of sufficient severity to make the patient desire therapeutic intervention)
  • Presence of hot flashes for >= 1 month prior to registration
  • Life expectancy >= 6 months
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Negative pregnancy test done =< 7 days prior to registration for women of childbearing potential only

Exclusion Criteria:

  • Any of the following current (=< last 4 weeks) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for >= 4 weeks and must not be expected to stop the medication during the study period): antineoplastic chemotherapy, androgens, estrogens, progestational agents, other herbal supplements, including soy, vitamin E, flaxseed, and megadose vitamins (herbal teas, multivitamins, and vitamin D are allowed), warfarin (1 mg of daily warfarin is allowed for central line patency), medications interacting with SAMe (antidepressants, monoamine oxidase (MAO) inhibitors, meperidine, dextromethorphan, pentazocine, tramadol, gabapentin, and levodopa)
  • Pregnant women
  • Nursing women
  • Women of childbearing potential who are unwilling to employ adequate contraception
  • Known allergy to SAMe
  • Current use or use within the past 6 months of SAMe
  • Clinically significant acute or chronic progressive or unstable neurologic, psychiatric, hepatic, renal, cardiovascular, respiratory, metabolic, or systemic disease precluding participation in the study
  • History of bipolar disorder or Parkinsonism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01140646

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Study Chair: Amit Sood, M.D. Mayo Clinic
  More Information

Responsible Party: Mayo Clinic Identifier: NCT01140646     History of Changes
Other Study ID Numbers: MC09C4
NCI-2010-01224 ( Registry Identifier: NCI's CTRO )
MC09C4 ( Other Identifier: Mayo Clinic Cancer Center )
10-001896 ( Other Identifier: Mayo Clinic IRB )
Study First Received: June 8, 2010
Results First Received: January 10, 2014
Last Updated: April 10, 2014

Keywords provided by Mayo Clinic:
Hot flashes, dietary supplements, symptom management

Additional relevant MeSH terms:
Hot Flashes
Signs and Symptoms processed this record on July 21, 2017